Bristol-Myers Squibb Company (BMY)

NYSE: BMY · IEX Real-Time Price · USD
48.82
-0.11 (-0.21%)
Nov 29, 2023, 11:05 AM EST - Market open
-0.21%
Market Cap 99.35B
Revenue (ttm) 44.94B
Net Income (ttm) 8.29B
Shares Out 2.03B
EPS (ttm) 3.94
PE Ratio 12.42
Forward PE 6.36
Dividend $2.28 (4.67%)
Ex-Dividend Date Oct 5, 2023
Volume 2,182,846
Open 49.06
Previous Close 48.92
Day's Range 48.81 - 49.35
52-Week Range 48.42 - 81.44
Beta 0.37
Analysts Buy
Price Target 64.65 (+32.44%)
Earnings Date Oct 26, 2023

About BMY

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; Orencia for adult patients with active RA and p... [Read more]

Sector Healthcare
Founded 1887
Employees 34,300
Stock Exchange NYSE
Ticker Symbol BMY
Full Company Profile

Financial Performance

In 2022, BMY's revenue was $46.16 billion, a decrease of -0.49% compared to the previous year's $46.39 billion. Earnings were $6.33 billion, a decrease of -9.54%.

Financial Statements

Analyst Forecast

According to 18 analysts, the average rating for BMY stock is "Buy." The 12-month stock price forecast is $64.65, which is an increase of 32.44% from the latest price.

Price Target
$64.65
(32.44% upside)
Analyst Consensus: Buy
Stock Forecasts

News

3 stocking stuffers you can buy for yourself

Stocking stuffers are small, inexpensive presents that help to complete the holiday, so for this screen, the focus was on inexpensive stocks. Inexpensive means a low P/E multiple relative to the S&P 5...

Other symbols: ISTRSJM
4 hours ago - MarketBeat

Avidity Stock Soars on Collaboration Deal With Bristol Myers

Bristol Myers has agreed to pay Avidity $60 million in cash and will also purchase about $40 million of Avidity common stock at $7.88 a share.

Other symbols: RNA
1 day ago - Barrons

Avidity's stock soars on news of expanded collaboration with Bristol Myers that includes potential to receive up to $2.2 billion in milestone payments

Avidity Biosciences Inc. RNA said Tuesday it's expanding its cardiovascular collaboration with Bristol Myers Squibb Co. BMY in a deal that will see Avidity receive $100 million upfront with the potent...

Other symbols: RNA
1 day ago - Market Watch

Three-Stock Lunch: Boeing, Bristol Myers and Krispy Kreme

Sylvia Jablonski, Defiance ETFs CEO and CIO, joins 'Power Lunch' ' to discuss three stocks: Boeing, Bristol Myers and Krispy Kreme Inc.

Other symbols: BADNUT
8 days ago - CNBC Television

Midday Movers: Boeing and GM Advance, Bristol-Myers Squibb Declines

U.S. equities began the Thanksgiving holiday-shortened trading week higher at midday after optimism about slowing inflation buoyed markets last week. The Dow, S&P 500, and Nasdaq all gained.

Other symbols: BAGM
8 days ago - Investopedia

Bristol-Myers Squibb, 2seventy Bio Shares Fall as FDA Delays Decision on Cancer Drug

Shares of Bristol-Myers Squibb (BMY) and partner 2seventy bio (TSVT) slumped after the two companies announced that the Food and Drug Administration (FDA) would not make a decision on expanded use for...

Other symbols: TSVT
8 days ago - Investopedia

Bristol Myers Squibb Stock Falls After Drug Approval Delayed

Abecma, developed with 2seventy Bio, won't be approved for earlier treatments of a certain kind of blood cancer by a Dec. 16 deadline.

9 days ago - Barrons

Bristol Myers Squibb, 2seventy bio shares fall as FDA delays action on cancer treatment

Shares of Bristol Myers Squibb Co. BMY and 2seventy bio Inc. TSVT fell premarket on Monday after the companies said the U.S. Food and Drug Administration would miss its target date for potential appro...

Other symbols: TSVT
9 days ago - Market Watch

US FDA delays decision on Bristol Myers-2seventy bio cancer therapy

The U.S. Food and Drug Administration (FDA) will not make a decision on Bristol Myers Squibb and 2seventy bio's marketing application of their blood cancer therapy, Abecma, for earlier lines of treatm...

Other symbols: TSVT
9 days ago - Reuters

Bristol Myers Squibb and 2seventy bio Provide Update on U.S. FDA Review of sBLA for Abecma (idecabtagene vicleucel) in Earlier Lines of Therapy for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma

PRINCETON, N.J. & CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $BMY #2seventy--BMS and 2seventy bio Provide Update on U.S. FDA Review of sBLA for Abecma (idecabtagene vicleucel).

9 days ago - Business Wire

2 overlooked stocks that crushed earnings but traded lower

As the third quarter 2023 earnings season ends, it's worth looking back to see which stocks may have been overlooked or mispriced on their results. Regardless of sector or industry, every earnings sea...

Other symbols: WHR
9 days ago - MarketBeat

Pharma Is Out of Favor. 5 Drug Stocks With Room to Grow.

Despite Eli Lilly's monster 66.8% gain on the year because of weight-loss drugs, the S&P 500 Pharmaceuticals index is down 2.3%.

Other symbols: JNJLLYPFEPPH
13 days ago - Barrons

U.S. Food and Drug Administration Approves Augtyro™ (repotrectinib), a Next-Generation Tyrosine Kinase Inhibitor (TKI), for the Treatment of Locally Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer (NSCLC)

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #Augtyro--U.S. Food and Drug Administration Approves Augtyro™ (repotrectinib), a Next-Generation Tyrosine Kinase Inhibitor (TKI), for the Treatment.

13 days ago - Business Wire

US FDA approves Bristol-Myers' lung cancer drug

The U.S. Food and Drug Administration (FDA) on Wednesday approved Bristol-Myers' drug to treat patients with a type of lung cancer.

13 days ago - Reuters

High-yield, low-beta value plays for buy-and-hold investors

With risk omnipresent in the market and more reason than 1 to fear a recession, value, yield, and beta are more critical for successful investing than ever. If nothing else, volatility should be expec...

Other symbols: CVSBGSVZ
15 days ago - MarketBeat

Is Bristol Myers Squibb Stock Undervalued At $50?

Bristol Myers Squibb (NYSE: BMY) reported its Q3 results last month, with revenues meeting and earnings beating the street estimates, and we believe that BMY stock is

19 days ago - Forbes

Bristol Myers Squibb to Participate in the 2023 Jefferies London Healthcare Conference

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb to Participate in the 2023 Jefferies London Healthcare Conference.

19 days ago - Business Wire

Fortunes Can Be Made With Bristol-Myers Squibb

Since early July, Bristol-Myers Squibb Co.'s (BMY, Financial) share price has been under downward pressure due, in part, to growing concerns among financial market participants about the ability of it...

19 days ago - GuruFocus

U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb's Application for Breyanzi (lisocabtagene maraleucel) for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #BMS--FDA Accepts for Priority Review Bristol Myers Squibb's Application for Breyanzi for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or .

20 days ago - Business Wire

Why this Dow stock went from worst in 2022 to first in 2023 — and 13 turnaround candidates for 2024

Stocks' yearly performance rankings are a field day for contrarians: One year's worst often are the subsequent year's best, and vice versa.

Other symbols: CRMNVDACCICFGCMAESKEY
20 days ago - Market Watch

MIRATI THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Mirati Therapeutics, Inc. - MRTX

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Mirati Therapeut...

Other symbols: MRTX
20 days ago - Business Wire

Tempus Announces Research Collaboration with Bristol Myers Squibb to Apply Multimodal AI Approaches

CHICAGO--(BUSINESS WIRE)--Tempus, a leader in artificial intelligence and precision medicine, today announced a multi-year, strategic research collaboration with Bristol Myers Squibb (NYSE: BMY). The ...

21 days ago - Business Wire

Bristol Myers buys Orum's blood cancer therapy for up to $180 mln

Bristol Myers Squibb has acquired Orum Therapeutics' experimental therapy to treat a type of blood cancer for a total value of up to $180 million, the privately held company said on Monday.

23 days ago - Reuters

Orum Therapeutics Announces Acquisition of ORM-6151 Program by Bristol Myers Squibb

BOSTON & DAEJEON, South Korea--(BUSINESS WIRE)-- #ADC--Orum Therapeutics Announces Acquisition of ORM-6151 Program by Bristol Myers Squibb.

23 days ago - Business Wire

Bristol Myers Squibb to Present Data from Innovative Cardiovascular Portfolio at the American Heart Association Scientific Sessions 2023

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #BMS--Bristol Myers Squibb to Present Data from Innovative Cardiovascular Portfolio at the American Heart Association Scientific Sessions 2023.

23 days ago - Business Wire